Somatostatin, growth hormone, insulin-like growth factor-1, and diabetes: Friends or foes?
- 31 August 1996
- journal article
- review article
- Published by Elsevier in Metabolism
- Vol. 45, 91-95
- https://doi.org/10.1016/s0026-0495(96)90094-3
Abstract
No abstract availableKeywords
This publication has 50 references indexed in Scilit:
- Randomized double-blind Scandinavian trial of angiopeptin versus placebo for the prevention of clinical events and restenosis after coronary balloon angioplastyAmerican Heart Journal, 1995
- Dose-dependent stimulation of insulin-like growth factor-binding protein-1 by lanreotide, a somatostatin analogJournal of Clinical Endocrinology & Metabolism, 1994
- Somatostatin-stimulated insulin-like growth factor binding protein-1 release is abolished by hyperinsulinemiaJournal of Clinical Endocrinology & Metabolism, 1994
- Octreotide administration in diabetic rats: Effects on renal hypertrophy and urinary albumin excretionKidney International, 1992
- Growth factors in pathogenesis of coronary arterial restenosisThe American Journal of Cardiology, 1991
- Insulin-like growth factor I gene expression in vascular cells.Hypertension, 1991
- Somatostatin analogue, octreotide, reduces increased glomerular filtration rate and kidney size in insulin-dependent diabetesJAMA, 1991
- Receptors for insulin-like growth factor-I in plasma membranes isolated from bovine mesenteric arteriesActa Endocrinologica, 1988
- Pathogenesis of the Dawn Phenomenon in Patients with Insulin-Dependent Diabetes MellitusNew England Journal of Medicine, 1985
- Normalization of growth hormone hyperresponse to exercise in juvenile diabetics after “normalization” of blood sugarJournal of Clinical Investigation, 1971